KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Leases (2019 - 2026)

Bio-Rad Laboratories has reported Leases over the past 8 years, most recently at $161.9 million for Q1 2026.

  • Quarterly Leases rose 5.68% to $161.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $161.9 million through Mar 2026, up 5.68% year-over-year, with the annual reading at $170.0 million for FY2025, 5.92% up from the prior year.
  • Leases was $161.9 million for Q1 2026 at Bio-Rad Laboratories, down from $170.0 million in the prior quarter.
  • Over five years, Leases peaked at $200.0 million in Q3 2023 and troughed at $153.2 million in Q1 2025.
  • The 5-year median for Leases is $180.3 million (2025), against an average of $178.8 million.
  • Year-over-year, Leases grew 16.55% in 2023 and then dropped 18.91% in 2025.
  • A 5-year view of Leases shows it stood at $181.0 million in 2022, then grew by 7.6% to $194.7 million in 2023, then decreased by 17.57% to $160.5 million in 2024, then grew by 5.92% to $170.0 million in 2025, then decreased by 4.76% to $161.9 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Leases are $161.9 million (Q1 2026), $170.0 million (Q4 2025), and $180.3 million (Q3 2025).